Executive SummaryHas completed new round of venture capital financing totaling $ 9.25 mil., Cambridge, Mass.-based start-up said Aug. 22. Investors include Bristol-Myers Squibb. Procept is developing receptor-based therapeutics for immune system diseases, with a focus on AIDS, autoimmune disease, organ transplant rejection and allergy.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.